Abstract
For many years, ivermectin has been widely distributed throughout west Africa for the safe and effective control of onchocerciasis. However, recent events in Loa-loa-endemic areas of Cameroon, where severe adverse reactions have occurred, now constrain the public-health use of this drug in the forest habitat of the L loa vector. We have created a model of L loa prevalence to identify areas where high endemicity may be associated with the occurrence of such reactions. The model results have been mapped and the areas of overlap between high L loa prevalence and planned ivermectin distribution for onchocerciasis control identified.
| Original language | English |
|---|---|
| Pages (from-to) | 1077-1078 |
| Number of pages | 2 |
| Journal | The Lancet |
| Volume | 356 |
| Issue number | 9235 |
| DOIs | |
| Publication status | Published - 23 Sept 2000 |